TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06599580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training caregivers to screen children for malnutrition relapse
Description: Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training caregivers to screen children for malnutrition relapse
Description: Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced follow-up schedule
Description: Caregivers in one of the caregiver mid-upper arm circumference screening arms, will be asked to adhere to a reduced follow-up clinic visit schedule for when they bring their child to the clinic for planned visits. The standard of care includes monthly visits for the first 3 months post recovery, but those randomized to the reduced follow-up schedule arm, will not bring their child to the clinic for planned visits 1 month and 2 months after baseline.
Study: NCT06588842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cluster Set Resistance Training
Description: Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets and 15-second rests after repetitions three and six.
Study: NCT04936230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05516745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AioCare spirometer
Description: In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AioCare spirometer
Description: In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabiliation of the respiratory system
Description: A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabiliation of the respiratory system
Description: A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
Study: NCT06430021

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 8 mL blood sample in EDTA tube
Study: NCT06429397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and Penpulimab
Description: Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
Study: NCT00733200

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Minor or Major Liver Resection
Study: NCT06588842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Set Resistance Training
Description: Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets.
Study: NCT06668805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Modified recombinant human C-type natriuretic peptide Vosoritide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Modified recombinant human C-type natriuretic peptide Vosoritide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Modified recombinant human C-type natriuretic peptide Vosoritide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Commercial product containing somatotropin.
Study: NCT06614712

Intervention type: OTHER
Intervention: Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)
Description: Incident renal disease patients in this cohort are defined as those that newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the start date of this cohort study period, the 1st August 2020 and until the 1 st February 2023 (DAPA_CKD P\&R date in Spain). The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-1 of this study cohort.~At the index date-1, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines.~Patients will be followed up from the index date-1 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall observation period.

Intervention type: OTHER
Intervention: Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)
Description: We define the post-P\&R cohort including all incident renal disease patients observed in the dapagliflozin-CKD post-pricing and reimbursement period. Patients in this cohort newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the 1 st February 2023 (DAPA_CKD P\&R date in Spain) and until the end of the study observation period. The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-2 of this study cohort. At the index date-2, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines. Patients will be followed up from the index date-2 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall study period
Study: NCT05437770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR (Blood-Flow Restricted exercise)
Description: The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
Study: NCT06072157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK006-IV
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK006-IV
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK006-IV
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-IV
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-IV
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-IV
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK006-SC
Description: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-SC
Description: Subcutaneous
Study: NCT06132282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use and Health Risk Intervention (SUHRI)
Description: Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
Study: NCT03850964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: gel capsule, with 25mg-similar fills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: gel capsule, with 25mg-similar fills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: gel capsule, with 25mg-similar fills
Study: NCT05073003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: altSonflex Placebo
Description: 2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
Study: NCT06611319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevention of Venous Thromboembolism
Description: Direct oral anticoagulant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevention of Venous Thromboembolism
Description: Direct oral anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT06672081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Catheter-Interventional Treatment
Description: Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional care
Description: reperfusion treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: reperfusion treatment
Study: NCT06591026

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: One digital helpline session that includes a structured motivational interviewing brief intervention.
Study: NCT03850964

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: identical gel capsule without active pharmaceutical ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: identical gel capsule without active pharmaceutical ingredient
Study: NCT05086224

Intervention type: DRUG
Group type: OTHER
Intervention: Hematoma Local Anesthetic Block Procedure with 1% Lidocaine
Description: Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.

Intervention type: DRUG
Group type: OTHER
Intervention: Bier Anesthetic Block Procedure with 1% Lidocaine
Description: Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
Study: NCT05130632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The community working group
Description: The intervention consists of educational working group (WG) sessions over a 12-week period. Eight core modules-the essential ingredients-and 4 periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize 1 task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as: -starting an organic compost pile free of plastic waste -training on community recycling, focusing on plastics recycling -making organic soaps, to use for personal grooming or washing clothes, eliminate plastic packaging -creating materials out of plastic, like bottle planters, crocheted plastic bags, purses.
Study: NCT05475483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 capsules
Description: Treatment will be blind for the whole duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 capsules
Description: Treatment will be blind for the whole duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Treatment will be blind for the whole duration of the study.
Study: NCT06040918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: fixed dose of 1 mg by subcutaneous (SC) injection
Study: NCT06162663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant Tablets
Description: Suvorexant initially with 10-20 mg for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Matched Placebo Control for 28 days
Study: NCT04545723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FibriCheck
Description: FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
Study: NCT04628169

Intervention type: OTHER
Intervention: no intervention applied
Description: no intervention applied

Intervention type: OTHER
Intervention: no intervention applied
Description: no intervention applied
Study: NCT05609994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEPIDH1M vaccine + vorasidenib
Description: Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
Study: NCT05609877

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline will be administered intravenously instead of pre-procedure analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Less Invasive Surfactant Administration (LISA)
Description: All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Less Invasive Surfactant Administration (LISA)
Description: All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacological standard operating procedure
Description: All infants will receive the same non-pharmacological standard operating procedure.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-pharmacological standard operating procedure
Description: All infants will receive the same non-pharmacological standard operating procedure.
Study: NCT05866679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13-C-pyruvate
Description: Given by PO
Study: NCT06044909

Intervention type: PROCEDURE
Intervention: Minimal invasive hepatectomy, intraoperative stage
Description: Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.

Intervention type: PROCEDURE
Intervention: Minimal invasive hepatectomy, postoperative stage
Description: The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.

Intervention type: OTHER
Intervention: Preoperative data collection
Description: Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.

Intervention type: OTHER
Intervention: Intraoperative data collection
Description: Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.

Intervention type: OTHER
Intervention: Postoperative data collection
Description: Definitive anatomical pathology with the measurement of resection margins.